Gimeno-Gracia Mercedes, Crusells-Canales María José, Armesto-Gómez Francisco Javier, Compaired-Turlán Vicente, Rabanaque-Hernández María José
Pharmacy Department, Lozano Blesa University Clinical Hospital, Aragon Institute for Health Research.
Department of Infectious Diseases, Aragon Institute for Health Research, Lozano Blesa University Clinical Hospital.
Clin Interv Aging. 2016 Aug 26;11:1149-57. doi: 10.2147/CIA.S108072. eCollection 2016.
The percentage of older HIV-positive patients is growing, with an increase in age-related comorbidities and concomitant medication.
To quantify polypharmacy and profile types of non-antiretroviral drugs collected at community pharmacies in 2014 by HIV-positive individuals on antiretroviral therapy and to compare these findings with those of the general population.
HIV-positive patients (n=199) were compared with a group of patients from the general population (n=8,172), aged between 50 and 64 years. The factors compared were prevalence of polypharmacy (≥5 comedications with cumulative defined daily dose [DDD] per drug over 180), percentage of patients who collected each therapeutic class of drug, and median duration for each drug class (based on DDD). Results were stratified by sex.
Polypharmacy was more common in HIV-positive males than in the male general population (8.9% vs 4.4%, P=0.010). Polypharmacy was also higher in HIV-positive females than in the female general population (11.3% vs 3.4%, P=0.002). Percentage of HIV-positive patients receiving analgesics, anti-infectives, gastrointestinal drugs, central nervous system (CNS) agents, and respiratory drugs was higher than in the general population, with significant differences between male populations. No differences were observed in proportion of patients receiving cardiovascular drugs. The estimated number of treatment days (median DDDs) were higher in HIV-positive males than in males from the general population for anti-infectives (32.2 vs 20.0, P<0.001) and CNS agents (238.7 vs 120.0, P=0.002). A higher percentage of HIV-positive males than males from the general population received sulfonamides (17.1% vs 1.5%, P<0.001), macrolides (37.1% vs 24.9%, P=0.020), and quinolones (34.3% vs 21.2%, P=0.009).
Polypharmacy is more common in HIV-positive older males and females than in similarly aged members of the general population. HIV-positive patients received more CNS drugs and anti-infectives, specifically sulfonamides, macrolides, and quinolones, but there were no differences in the percentage of patients receiving cardiovascular drugs. It is essential to investigate nonantiretroviral therapy medication use in the HIV-positive population to ensure these patients receive appropriate management.
老年HIV阳性患者的比例正在增加，与年龄相关的合并症和伴随用药也在增多。
量化2014年接受抗逆转录病毒治疗的HIV阳性个体在社区药房所取非抗逆转录病毒药物的多重用药情况及药物类型，并将这些结果与普通人群的结果进行比较。
将199名HIV阳性患者与一组年龄在50至64岁之间的普通人群患者（n = 8172）进行比较。比较的因素包括多重用药的患病率（≥5种合并用药，每种药物的累积限定日剂量[DDD]超过180）、领取每种治疗类药物的患者百分比以及每种药物类别的中位使用时长（基于DDD）。结果按性别分层。
HIV阳性男性的多重用药情况比普通男性人群更常见（8.9%对4.4%，P = 0.010）。HIV阳性女性的多重用药情况也高于普通女性人群（11.3%对3.4%，P = 0.002）。接受镇痛药、抗感染药、胃肠道药物、中枢神经系统（CNS）药物和呼吸系统药物的HIV阳性患者百分比高于普通人群，男性人群之间存在显著差异。在接受心血管药物治疗的患者比例方面未观察到差异。HIV阳性男性使用抗感染药（32.2对20.0，P<0.001）和CNS药物（238.7对120.0，P = 0.002）的估计治疗天数（中位DDD）高于普通男性人群。接受磺胺类药物（17.1%对1.5%，P<0.001）、大环内酯类药物（37.1%对24.9%，P = 0.020）和喹诺酮类药物（34.3%对21.2%，P = 0.009）的HIV阳性男性百分比高于普通男性人群。
HIV阳性的老年男性和女性的多重用药情况比普通人群中年龄相仿的成员更常见。HIV阳性患者使用了更多的CNS药物和抗感染药，特别是磺胺类药物、大环内酯类药物和喹诺酮类药物，但在接受心血管药物治疗的患者百分比方面没有差异。调查HIV阳性人群中非抗逆转录病毒治疗药物的使用情况对于确保这些患者得到适当管理至关重要。
